Durect_FINAL-FINISHED-01_2022.png

ABOUT US

DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program. DURECT is focusing its efforts on therapeutic areas with significant unmet need, including diseases with no approved treatments like alcohol-associated hepatitis (AH) and non-alcoholic steatohepatitis (NASH)

Gail-Friedt.jpg

Contact

Gail Friedt, MSN, RN

Sr. Medical Science Liaison

DURECT Corporation

(650) 722-8176

gail.friedt@durect.com

www.durect.com

@DURECTCorp